Prevalence of HIV/hepatitis B and HIV/hepatitis C coinfection among people of East, South, Central and West African ancestry in the United Kingdom
Rachel Hung, Nisha Patel, Julie Fox, Catherine Cosgrove, Sarah L Pett, Fiona Burns, Andrew Ustianowski, Melanie Rosenvinge, Sanjay Bhagani, Geoff Dusheiko, Kate Childs, Frank A Post, GEN-AFRICA study group, Rachel Hung, Nisha Patel, Julie Fox, Catherine Cosgrove, Sarah L Pett, Fiona Burns, Andrew Ustianowski, Melanie Rosenvinge, Sanjay Bhagani, Geoff Dusheiko, Kate Childs, Frank A Post, GEN-AFRICA study group
Abstract
Regional variability in the prevalence of hepatitis B (HBV) and C (HCV) is reported in sub-Saharan Africa, although data for people with HIV are sparse. We determined the prevalence of HBV/HCV in 2473 people of African ancestry with HIV in the UK. Overall, 6.2% were co-infected with HBV and 1.3% with HCV. Central [adjusted odds ratio (aOR) 2.40 (95% confidence interval (CI) 1.23--4.67) and West [2.10 (1.29-3.41)] African ancestry was associated with HBV and Central [6.98 (2.00-24.43)] African ancestry with HCV.
Conflict of interest statement
Conflict of Interest Statement
JF reports grant funding from Gilead. AU reports personal feed from Janssen, Gilead, MSD and ViiV. SB reports grants and/or personal fees from Gilead Sciences, Janssen, MSD, Roche and ViiV. GD reports grants from Abbott, personal fees from Gilead and Arbutus (donated to a registered charity), and personal fees for membership of a Drug Safety Monitoring Board from Enanta, Janssen, Glaxo Smith Kline and Aligos. FAP reports grants and/or personal fees from Gilead Sciences, ViiV, Janssen, and MSD. All others report no conflicts of interest.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Source: PubMed